Argen X SE ADR

ARGXNASDAQ · USD
960.04USD0.00 (-2.17%)
529

Argen X SE ADR (ARGX) Historical Volatility

ARGX's 30 day historical volatility is 51.46%, in the 90th percentile of readings over the past year. This is a high percentile, meaning Argen X SE ADR shares have swung far more than usual. ARGX's 30 day implied volatility sits at 40.73%, with an IV Rank of 69.05%, leaving IV 10.73 points below historical volatility. This means options are pricing in less movement than the stock has actually delivered, as of Nov 13, 2026.

Read more

Tracking ARGX historical volatility helps you see how much Argen X SE ADR's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, ARGX's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor ARGX 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.

Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. ARGX's 30 day historical volatility, or ARGX HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing ARGX's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Historical Volatility

HV Percentile
90thHV Percentile
High

Historical movement is elevated versus the past year. The stock has been unusually active.

Historical Volatility (30d)51.46%

HV Percentile90th

Implied Volatility (30d)40.73%

IV Rank69.05%

IV Minus HV-10.73%

As of Nov 13, 2026

IV vs HV
Implied Volatility (IV) vs Historical Volatility (HV) over the past month.

As of Nov 13, 2026

IV - HV Difference
Difference between IV and HV over time. Positive values indicate IV > HV.

As of Nov 13, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →